S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
NASDAQ:KZR

Kezar Life Sciences Stock Forecast, Price & News

$12.62
+0.32 (+2.60%)
(As of 01/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.41
$12.64
50-Day Range
$8.41
$16.72
52-Week Range
$4.61
$17.28
Volume
536,988 shs
Average Volume
504,826 shs
Market Capitalization
$620.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.16
30 days | 90 days | 365 days | Advanced Chart
Receive KZR News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.


Kezar Life Sciences logo

About Kezar Life Sciences

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZR
Fax
N/A
Employees
47
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$3.05 per share

Profitability

Net Income
$-41.74 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
45,362,000
Market Cap
$620.22 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/24/2022
Next Earnings (Estimated)
3/10/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

847th out of 1,415 stocks

Pharmaceutical Preparations Industry

409th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions

Is Kezar Life Sciences a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kezar Life Sciences stock.
View analyst ratings for Kezar Life Sciences
or view top-rated stocks.

How has Kezar Life Sciences' stock been impacted by Coronavirus?

Kezar Life Sciences' stock was trading at $3.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KZR stock has increased by 216.3% and is now trading at $12.62.
View which stocks have been most impacted by COVID-19
.

When is Kezar Life Sciences' next earnings date?

Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Kezar Life Sciences
.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.02.
View Kezar Life Sciences' earnings history
.

What price target have analysts set for KZR?

3 brokers have issued 1-year target prices for Kezar Life Sciences' stock. Their forecasts range from $14.00 to $20.00. On average, they anticipate Kezar Life Sciences' stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 40.0% from the stock's current price.
View analysts' price targets for Kezar Life Sciences
or view top-rated stocks among Wall Street analysts.

Who are Kezar Life Sciences' key executives?

Kezar Life Sciences' management team includes the following people:
  • John Fowler, Chief Executive Officer & Director
  • Christopher J. Kirk, President, Director & Chief Scientific Officer
  • Michael Wolfe, Director-Finance & Business Operations
  • Marc L. Belsky, Chief Financial Officer & Secretary
  • Noreen Roth Henig, Chief Medical Officer

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (0.21%). Company insiders that own Kezar Life Sciences stock include Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Michael Kauffman, Morningside Venture Investment and Vassiliki Economides.
View institutional ownership trends for Kezar Life Sciences
.

Which major investors are buying Kezar Life Sciences stock?

KZR stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. Company insiders that have bought Kezar Life Sciences stock in the last two years include Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Morningside Venture Investment, and Vassiliki Economides.
View insider buying and selling activity for Kezar Life Sciences
or or view top insider-buying stocks.

How do I buy shares of Kezar Life Sciences?

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $12.62.

How much money does Kezar Life Sciences make?

Kezar Life Sciences has a market capitalization of $620.22 million. The company earns $-41.74 million in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Kezar Life Sciences have?

Kezar Life Sciences employs 47 workers across the globe.

What is Kezar Life Sciences' official website?

The official website for Kezar Life Sciences is www.kezarlifesciences.com.

Where are Kezar Life Sciences' headquarters?

Kezar Life Sciences is headquartered at 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 822-5600 or via email at [email protected].


This page was last updated on 1/24/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.